The risk for hyperkalemia was highest with use of steroidal MRAs in combination with other RAASi.
Serum creatinine-based eGFR used alone overestimates kidney function and can lead to inaccurate dosing of medications in patients with cancer.
Only a subset of patients resume their usual RAASi treatment following a hyperkalemia episode, investigators found.
Antihypertensive regimens that include a mineralocorticoid receptor antagonist carry the highest risk for hyperkalemia.
The risks for sudden cardiac death from certain QT-prolonging antibiotics increase with steeper serum to dialysate potassium gradients.
Adverse events rates have been rising over time among patients receiving dialysis, investigators reported.
Patients with CKD at high risk of hyperkalemia based on the nomogram may benefit from intensive monitoring, according to investigators.
Medical nutritional therapy may need to be combined with anti-hyperkalemia therapy to prevent recurrence, investigators suggested.
Use of intravenous iron and ESAs was low among patients with stage 3 to 5 CKD.
Patients with stage 4 diabetic kidney disease are understudied and lack treatment options.